Biologics4Life Technology Provides New Clinical Option for Osteoporotic Patients

Biologics4Life has developed Neo-S, a patent-pending technology. Neo-S bone graft substitute is combined with an active principle to form an advanced biomaterial which addresses the needs of patients with osteoporosis or bone metastasis. This patent will strengthen the company’s intellectual property portfolio and is a major step in the development of its range of combination orthobiologic materials.

“Neo-S is the result of 3 years of extensive research conducted by our creative multidisciplinary R&D team and our distinguished French academic partners; it will address unmet clinical needs in the treatment and prevention of fractures induced by metabolic bone disorders”, commented Sébastien Genesta, COO.

Biologics4Life, an early stage orthobiologics company, conceives, develops and manufactures a range of patented biomaterials for bone regeneration, including Neo-S and Neo Visc injectable bone substitute.